Key result
MitoQ improves post-MI hemodynamics and reduces mitochondrial ROS production in preclinical models.
Why the study?
Acute myocardial infarction is the leading cause of heart failure, but the role of mitochondrial ROS in early post-infarction myocardial dysfunction remains unclear.
Does MitoQ improve cardiac function and reduce mitochondrial ROS in a rat model of acute myocardial infarction?
Does MitoQ improve cardiac function and reduce mitochondrial ROS in a rat model of acute myocardial infarction?
Targeting mitochondrial oxidative stress with MitoQ in the acute phase of myocardial infarction prevents contractile dysfunction and adverse remodeling in a preclinical model.
MitoQ may attenuate post-MI dysfunction in rats; leaves open human translation and clinical testing.
Acute myocardial infarction (MI) is the leading cause of heart failure (HF). However, the role of mitochondrial ROS (ROSm) in early MI dysfunction remains unclear. This study aimed to evaluate the impact of MitoQ on cardiac function in cases of heart HF following MI. Male Wistar rats were divided into four experimental groups: Sham, Infarct, Sham+MitoQ, and Infarct+MitoQ. MitoQ was administered orally (8 mg/kg/dia) for 7 days. Hemodynamic parameters, infarct area, papillary muscle contractility, cardiomyocyte mechanics, Ca 2+ transients, and total and mitochondrial superoxide (DHE and MitoSOX) were assessed. After 7 days of MI, rats exhibited impaired contractility, altered inotropic response to extracellular Ca 2+ , cardiomyocyte hypertrophy, and increased total and ROSm. MitoQ prevented body weight loss and significantly improved hemodynamic parameters compared to the Infarct group. In papillary muscles, MitoQ restored basal isometric force and the inotropic response to extracellular Ca 2+ . In cardiomyocytes, it attenuated hypertrophy, preserved shortening, and reduced ([Ca 2+ ]i) transient amplitude. MitoQ significantly decreased total and mitochondrial O 2 • − production. It selectively reduced NOX1 expression under simulated conditions but did not significantly affect NOX2, SOD1, or catalase expression in the context of MI. MitoQ prevented contractile dysfunction, suggesting that mitochondrial oxidative stress plays a decisive role in myocardial dysfunction during the acute phase of MI. Targeting antioxidant therapy to the mitochondria represents a promising strategy for preventing post‐infarction heart failure and opens new perspectives for the development of more effective interventions in the treatment of cardiovascular diseases.
No takes yet. Share an insight, caveat, or question.
Ximenes et al. (2026) studied Acute myocardial infarction. Mitoquinone (MitoQ) vs. Untreated myocardial infarction (Infarct group) and Sham-operated rats was evaluated on Hemodynamic parameters, cardiomyocyte contractility, and mitochondrial ROS production (p=<0.05). MitoQ administration for 7 days post-myocardial infarction significantly improved hemodynamic parameters and reduced mitochondrial ROS production compared to untreated infarction.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: